JPY 1802.0
(2.97%)
Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|---|
Operating Cash Flow | 19.17 Billion | 15.59 Billion | 15.5 Billion | 3.51 Billion | 4.81 Billion | 5.02 Billion |
Net Income | 10.43 Billion | 13.1 Billion | 10.23 Billion | 5.04 Billion | 3.26 Billion | 5.6 Billion |
Depreciation & Amortization | 2.15 Billion | 2.24 Billion | 3 Billion | 2.73 Billion | 1.2 Billion | 1.03 Billion |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | 5.4 Billion | 2.8 Billion | 438 Million | 318 Million | 552 Million | 365 Million |
Other non-cash items | 7.45 Billion | -2.54 Billion | 1.81 Billion | -4.58 Billion | -209 Million | -1.97 Billion |
Investing Cash Flow | -5.02 Billion | 611 Million | -2.16 Billion | -1.35 Billion | -1.98 Billion | -1.43 Billion |
Investments in PPE | -730 Million | -727 Million | -565 Million | -307 Million | -364 Million | -353 Million |
Acquisitions | -3.85 Billion | -73 Million | -1.49 Billion | -1.01 Billion | -1.32 Billion | -1.06 Billion |
Investment purchases | -700 Million | -18 Million | -82 Million | -175 Million | -207 Million | - |
Sales/Maturities of investments | 278 Million | 878 Million | -127 Million | -124 Million | -123 Million | - |
Other Investing Activities | -27 Million | 551 Million | 108 Million | 268 Million | 25 Million | -14 Million |
Financing Cash Flow | -8.88 Billion | -12.66 Billion | -22.04 Billion | -5.15 Billion | -1.83 Billion | -2.74 Billion |
Debt repayment | -182 Million | -638 Million | -8.71 Billion | -1.4 Billion | -743 Million | -1.58 Billion |
Dividends payments | -4.59 Billion | -3.96 Billion | -3.96 Billion | -1.78 Billion | -1.48 Billion | -1.38 Billion |
Common Stock Repurchased | -5 Million | -4.03 Billion | -4.05 Billion | -1.22 Billion | 1.01 Billion | 292 Million |
Common Stock Issuance | - | - | -4.87 Billion | 7 Million | 310 Million | 8 Million |
Other Financing Activities | 49 Million | -4.02 Billion | -439 Million | -745 Million | -923 Million | -87 Million |
Accounts receivables | -1.86 Billion | -1.4 Billion | 145 Million | -247 Million | 754 Million | -573 Million |
Accounts payables | -109 Million | -274 Million | - | - | - | - |
Inventory | - | 274 Million | - | - | - | - |
Other working capital | 7.37 Billion | 4.2 Billion | 293 Million | 565 Million | -202 Million | 938 Million |
Cash at beginning of period | 16.07 Billion | 12.4 Billion | 21.13 Billion | 11.15 Billion | 10.25 Billion | 9.41 Billion |
Cash at end of period | 21.5 Billion | 16.07 Billion | 12.4 Billion | 21.04 Billion | 11.15 Billion | 10.25 Billion |
Capital Expenditure | -730 Million | -727 Million | -565 Million | -307 Million | -364 Million | -353 Million |
Effect of forex changes on cash | 171 Million | 130 Million | -26 Million | 142 Million | -98 Million | -2 Million |
Net cash flow / Change in cash | 5.42 Billion | 3.67 Billion | -8.73 Billion | 9.88 Billion | 901 Million | 847 Million |
Free Cash Flow | 18.44 Billion | 14.87 Billion | 14.93 Billion | 3.2 Billion | 4.45 Billion | 4.67 Billion |
Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 2.24 Billion | 10.43 Billion | 2.78 Billion | 3.2 Billion | 3.31 Billion | 13.1 Billion |
Depreciation & Amortization | 603 Million | 2.15 Billion | 535 Million | 507 Million | 505 Million | 2.24 Billion |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | 3.17 Billion | 5.4 Billion | 1.34 Billion | -36 Million | 167 Million | 2.8 Billion |
Other non-cash items | 2.15 Billion | 7.45 Billion | 182 Million | 2.61 Billion | -1.44 Billion | -2.54 Billion |
Investing Cash Flow | -5.37 Billion | -5.02 Billion | -312 Million | 563 Million | 96 Million | 611 Million |
Investments in PPE | -248 Million | -730 Million | -140 Million | -180 Million | -162 Million | -727 Million |
Acquisitions | -4.6 Billion | -3.85 Billion | - | 750 Million | - | -73 Million |
Investment purchases | -700 Million | -700 Million | - | - | - | -18 Million |
Sales/Maturities of investments | 68 Million | 278 Million | 6 Million | - | 204 Million | 878 Million |
Other Investing Activities | 102 Million | -27 Million | -178 Million | -7 Million | 54 Million | 551 Million |
Financing Cash Flow | -652 Million | -8.88 Billion | -3.16 Billion | -1.05 Billion | -4.01 Billion | -12.66 Billion |
Debt repayment | -531 Million | -182 Million | -261 Million | -15 Million | -156 Million | -638 Million |
Dividends payments | -6 Million | -4.59 Billion | -1.73 Billion | -2 Million | -2.86 Billion | -3.96 Billion |
Common Stock Repurchased | -1 Million | -5 Million | -2 Million | -1 Million | -1 Million | -4.03 Billion |
Common Stock Issuance | - | - | - | -1.09 Billion | -999 Million | - |
Other Financing Activities | -2 Million | 49 Million | 29 Million | 58 Million | 3 Million | -4.02 Billion |
Accounts receivables | -625 Million | -1.86 Billion | -282 Million | -197 Million | -756 Million | -1.4 Billion |
Accounts payables | 104 Million | -109 Million | 406 Million | -37 Million | -582 Million | -274 Million |
Inventory | - | - | - | - | -750 Million | 274 Million |
Other working capital | 3.69 Billion | 7.37 Billion | 1.22 Billion | 198 Million | 2.25 Billion | 4.2 Billion |
Cash at beginning of period | 19.63 Billion | 16.07 Billion | 20.2 Billion | 14.7 Billion | 16.07 Billion | 12.4 Billion |
Cash at end of period | 21.5 Billion | 21.5 Billion | 19.63 Billion | 20.2 Billion | 14.7 Billion | 16.07 Billion |
Capital Expenditure | -248 Million | -730 Million | -140 Million | -180 Million | -162 Million | -727 Million |
Effect of forex changes on cash | 117 Million | - | 78 Million | -19 Million | -5 Million | 130 Million |
Net cash flow / Change in cash | 1.87 Billion | 5.42 Billion | -578 Million | 5.5 Billion | -1.37 Billion | 3.67 Billion |
Free Cash Flow | 6.19 Billion | 18.44 Billion | 3.76 Billion | 6.1 Billion | 2.38 Billion | 14.87 Billion |
CLTS
ROTS
UHG
035600
6070
RTERF